Eli Lilly and Company - Zepbound means change
Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a …
Savings Card, Cost & Coverage Support | Zepbound® (tirzepatide)
Estimated savings of up to $510 per month compared to the Zepbound pen. The vial is distributed in a one-month supply, defined as 28 days and 4 vials. Explore speed, convenience, and access to focused care with independent telehealth or in-person providers through LillyDirect.
How do I get Zepbound® (tirzepatide) vials? - medical.lilly.com
Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials. 1. Zepbound 2.5 and 5 mg vials are available.
Coverage, Affordability, and Savings | Zepbound® (tirzepatide)
Zepbound formulary coverage is at parity with Wegovy ® (semaglutide) for commercially insured patients * “Formulary coverage” is defined as Covered or Better formulary access, inclusive of preferred and covered statuses, and exclusive of specialty, not covered, or unknown statuses.
Zepbound® (tirzepatide) | Eli Lilly and Company
Dual-acting Zepbound is the only FDA-approved obesity management medication of its kind. It works differently by directly activating the receptors of GIP and GLP-1, two naturally occurring hormones. Learn about Zepbound and how it may help adults with obesity and adults with moderate-to-severe OSA and obesity:
FDA approves Zepbound® (tirzepatide) as the first and only …
Dec 20, 2024 · Zepbound ® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our ...
FDA Approves Lilly's Zepbound™ (tirzepatide ... - Eli Lilly and …
Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.
News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). Birth control pills by mouth may not work as well while using ZEPBOUND.
Eli Lilly to sell Zepbound directly to consumers without insurance ...
Aug 27, 2024 · Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect.